Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2000

View Archived Issues

New PDE4 inhibitors tested for antiinflammatory activities, GI side effects

Aphton's antigastrin vaccine increases survival in advanced pancreatic cancer; nears U.S. trials

Oxigene announces promising clinical results of CA4P in advanced solid tumors

Preclinical results for Avax's AC Vaccine technology in breast cancer presented at AACR

Sonus renegotiates EchoGen marketing rights with Abbott

Delivery of factor VIII gene using lentiviral vectors reported by Cell Genesys

AACR annual meeting chosen by ProIX as forum for presentation of novel class of redox regulators

Chirocaine launched in U.S. for anesthesia and pain management

Chinese evaluate new triptolide derivative T-12 with promising antitumor activity

Immune Response identifies genes involved in nerve repair

Lorus seeks to raise 30 million dollars in Canada to finance development programs

Oral calcitonin enters phase I/II trials

Forest signs agreement with Merckle for U.S. development and marketing of ML-3000

Potent and selective dual cdk1/cdk2 inhibitor emerges from Novartis R&D

Selective COX-2 inhibitor reported at AACR meeting to possess antiangiogenic and antitumor activity

AstraZeneca files NDA for zolmitriptan in Japan

Design and pharmacology of TSE-424, a potential osteoporosis therapy

FDA grants priority review to Zelmac for IBS

New NK1 antagonists with improved properties patented by Menarini

Yamanouchi prepares series of potent V1 receptor antagonists

Pfizer presents new therapeutics for atherosclerosis and associated conditions

New anti-H. pylori agents from Byk Gulden particularly suitable for administration by the oral route

Recent patent covers Icos's new phosphodiesterase inhibitors and their use

Novel series of PDE5 inhibitors claimed by Bristol-Myers Squibb for erectile dysfunction Rx

Parkinson's disease patients may benefit from implanted porcine embryonic cells

High antigen response to a single dose of liposomal hepatitis A vaccine

Sitafloxacin goes head-to-head with imipenem/cilastatin in phase II comparative trial

NPS Pharmaceuticals highlights clinical development program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....